| Identification | Back Directory | [Name]
Spiraprilat | [CAS]
83602-05-5 | [Synonyms]
SCH 33861
TI-213-864
Spiraprilate
Spiraprilatum
Spiraprilatum [inn-latin]
Spiraprilate [inn-french]
(3S)-2-[(S)-2-[[(S)-1-Carboxy-3-phenylpropyl]amino]propionyl]-2-aza-6,9-dithiaspiro[4.4]nonane-3-carboxylic acid
(8S)-7-[(2S)-2-[[(1S)-1-Carboxy-3-phenylpropyl]amino]-1-oxopropyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid
1,4-Dithia-7-azaspiro(4.4)nonane-8-carboxylic acid, 7-(2-((1-carboxy-3-phenylpropyl)amino)-1-oxopropyl)-, (8S-(7(R*(R*)),8R*))- | [Molecular Formula]
C20H26N2O5S2 | [MDL Number]
MFCD00865779 | [MOL File]
83602-05-5.mol | [Molecular Weight]
438.566 |
| Hazard Information | Back Directory | [Uses]
Spiraprilat is a potent angiotensin-converting enzyme (ACE) inhibitor. Spiraprilat has ability to improve left ventricular (LV) function and metabolism in anesthetized open-chest dogs with acute ventricular failure (ALVF)[1]. | [Definition]
ChEBI: Spiraprilat is an azaspiro compound that is spirapril in which the ethyl ester group has been hydrolysed to the corresponding carboxylic acid group. It is the active metabolite of the angiotensin-converting enzyme (ACE) inhibitor spirapril. It has a role as an antihypertensive agent, an EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor and a drug metabolite. It is an azaspiro compound, a dicarboxylic acid, a dipeptide, a dithioketal, a pyrrolidinecarboxylic acid, a secondary amino compound and a tertiary carboxamide. | [References]
[1] Nakazawa M, et al. Effects of spiraprilat, an angiotensin-converting enzyme inhibitor, on anesthetized dogs in a new model of acute left ventricular failure. J Cardiovasc Pharmacol. 1993 Oct;22(4):585-93. DOI:10.1097/00005344-199310000-00012 |
|
| Company Name: |
Leancare Ltd.
|
| Tel: |
+33 962096793 |
| Website: |
www.leancare.co.uk |
|